IPSEF - Ipsen S.A. reports 1H results, FY25 guidance
2025-07-31 13:24:58 ET
More on Ipsen S.A.
- Ipsen granted EU nod for Exelixis-partnered cancer drug for neuroendocrine tumors
- Madrigal, Ipsen, SpringWorks get EU backing for their drugs
- Historical earnings data for Ipsen S.A.
- Dividend scorecard for Ipsen S.A.
- Financial information for Ipsen S.A.